Grafting of human bone marrow stromal cells into spinal cord injury: a comparison of delivery methods.

Grafting of human bone marrow stromal cells into spinal cord injury: a comparison of delivery methods.
复制标题

DOI:
10.1097/brs.0b013e31819403ce
复制
发表时间:
2009-02-15
期刊:
影响因子:
3
通讯作者:
Neuhuber B
Neuhuber B
中科院分区:
医学2区
文献类型:
--
作者:
Paul C;Samdani AF;Betz RR;Fischer I;Neuhuber B

文献摘要

被引文献

相似文献

Three groups of 6 rats received subtotal cervical spinal cord hemisections followed with marrow stromal cell (MSC) transplants by lumbar puncture (LP), intravenous delivery (IV) or direct injection into the injury (control). Animals survived for 4 or 21 days. Cell therapy is a promising strategy for the treatment of spinal cord injury (SCI). The mode of cell delivery is crucial for the translation to the clinic. Injections directly into the parenchyma may further damage already compromised tissue; therefore, less invasive methods like LP or IV delivery are preferable. Human bone marrow stromal cells (MSC) are multipotent mesenchymal adult stem cells that have a potential for autologous transplantation, obviating the need for immune suppression. While previous studies have established that MSC can be delivered to the injured spinal cord by both LP and IV, the efficacy of cell delivery has not been directly compared with respect to efficacy of delivery and effects on the host. Purified MSC from a human donor were transplanted into the CSF at the lumbar region (LP), into the femoral vein (IV), or directly into the injury (control). After sacrifice, spinal cord sections were analyzed for MSC graft size, tissue sparing, host immune response, and glial scar formation, using specific antibodies as well as Nissl-myelin staining. LP delivery of MSC to the injured spinal cord is superior to IV delivery. Cell engraftment and tissue sparing were significantly better after LP delivery and host immune response after LP delivery was reduced compared to IV delivery. LP is an ideal minimally-invasive technique to deliver cellular transplants to the injured spinal cord. It is superior to IV delivery and, together with the potential for autologous transplantation, lends itself for clinical application.